(Isstories Editorial):- Llanymynech, United Kingdom Dec 19, 2024 (Issuewire.com) – M2M Capital Invests in GenpharmaChain to Drive AI and Web3-Powered Drug Development
GenPharmaChain, a pioneering AI-driven biotech Web3 platform, has secured a strategic investment from M2M Capital. The funding will accelerate GenPharmaChain’s mission to harness AI and blockchain technologies for transformative advancements in drug discovery and development.
More on Isstories:
- Why Lonovae, the China Top Sleeve Pack Containers Supplier, is Key to Unlocking the Future of Logistics
- The Future Leading PP Coaming Box Supplier for Tomorrow’s Sustainable and Customized Solutions
- Why Lonovae is a China Top Sleeve Pack Manufacturer: A Look at Its Leading Quality and Durability
- Manure Removal Made Easy: Your Guide to Belts from a China Top Manure Removal Belts Manufacturer
- Lonovae, a Future Leading PP Conveyor Belts Supplier, Showcases Pure PP for Overall Performance
With a robust database comprising over 200 million protein sequences and extensive disease-related data, GenPharmaChain seeks to revolutionize the pharmaceutical industry. By integrating decentralized platforms, the company aims to enable faster, more secure, and transparent drug development processes.
About M2M Capital
M2M Capital is a leading venture capital firm specializing in investments across cutting-edge sectors, including blockchain, AI, and Web3 technologies. The firm’s portfolio includes notable innovators such as Panda Titan and Nexgendex, underscoring its commitment to driving groundbreaking advancements in technology.
Source :Genpharmachain and M2M Capital
This article was originally published by IssueWire. Read the original article here.
